राष्ट्रीय प्रजनन एवं बाल स्वास्थ्य अनुसंधान संस्थान
National Institute for Research in Reproductive and Child Health
Regional Resource Centre: Health Technology Assessment India (HTAIn)
The Ministry of Health and Family Welfare, Department of Health Research under its research governance mandate has set up Health Technology Assessment India (HTAIn) to systematically evaluate the available and new health technologies in India to priorities national health spending. It is a tool that can be used in decision making for efficient use of limited health budget and provide people access to the quality health care thus reducing their out-of-pocket expenditures (OOPE) on health. More information available on https://htain.dhr.gov.in/
ICMR NIRRCH is one of the Regional Resource Hubs/Cantre’s established by HTAIn Department of Health Research MOHFW since 2017. It is entrusted with the responsibility to conduct HTA, and costing excercises on topics suggested by user departments and allocated by HTAIn Secretariat, liase with state and local public health departments to identify topics for conduct of HTA and disseminate results of studies conducted through HTAIn network for adoption into state health programs. Dr. Beena Joshi, Scientist G, Head Department Operational and Implementation Research is the Principal Investigator. The vision and mandate of NIRRCH as a Resource hub of HTA is line with that of HTAIn.
Health Technology Assessment (HTA) is defined as the systematic evaluation of properties, effects, and/or impacts of health technology. The word ‘technology’ can include interventions like drugs, devices, diagnostics, treatments, vaccines or health programs. It is a multidisciplinary process that summarizes information about the medical, economic, social, logistic, legal and ethical issues related to the use of health technology in a systematic, transparent, unbiased and robust manner. Its aim is to inform the formulation of safe, effective, health policies that are patient-focused and seek to achieve the best value. The evidence generated through HTA can be used by decision-makers and other stakeholders to support the decision-making process in health care at the policy level thus described as a bridge that connects the world of research to that of policy making.
Structure of NIRRCH HTA Regional Resource Hub
NIRRCH HTARegional Resource Hub Staff:
| S.No | Name | Designation |
| Principle Investigator | ||
| 1 | Dr. Beena Joshi | Scientist ‘G’ & Head Department of Operational and Implementation Research |
| HTAIn Resource Hub Staff | ||
| 2 | Dr.Pooja Gund | Scientist-D (Non-Medical) |
| 3 | Mr. Asim Kumar Padhan | Scientist ‘C’ (Non-Medical) |
| 4 | Ms. Tejal R Varekar | Project Scientist -II |
| 5 | Ms. Nikita Phadtare | Field Investigator |
| 6 | Mr.Nitin Narhari Mungekar | Administrative officer |
Projects (Ongoing):
| S. No. | Title of Project | Funding Agency |
| 1. | HWC Costing study on RMNCAH+N services/Assessment of RMNCAH+N Service delivery costs, work patterns and efficiency of primary healthcare teams at Ayushman Bharat -Health and wellness centres. | UNICEF |
| 2. | Health Technology Assessment To determine Cost-effectiveness of Hydroxyurea oral suspension as prophylaxis for management of Sickle cell Anemia in children | DHR |
| 3 | Cost-effectiveness of point-of-care test for detection of Thalassemia during antenatal screening as an alternative to the HPLC test conducted before twelve weeks of pregnancy. | DHR |
Projects (Completed):
| Sr.No | Title | Funding Agency | From | To |
| 1. | Cost-effectiveness of ferric carboxymaltose injection (IFA) to treat iron deficiency anemia among antenatal mothers. | DHR | 2025 | 2025 |
| 2. | Health Technology Assessment of Point of Care Test Kit for Hemophilia and Von Willebrand Disease (vWD) Screening developed at ICMR NIIH (approved by TAC) | HTA | 2023 | 2024 |
| 3. | To estimate the cost of diagnosis of infertility and its management including IVF and quality of life among infertile young couples. | DHR | 2023 | 2024 |
| 4. | To estimate the cost of diagnosis of infertility and its management including in-vitro fertilization and quality of life among infertile couple: A multicenter study (ICMR NIRRCH being the main lead center of the study) | DHR HTAIn | 2023 | 2024 |
| 5. | To determine Cost-effectiveness of Rapid Diagnostic Tests (Gazelle) in comparison to solubility test followed by HPLC for Sickle Cell Disease/Trait diagnosis among high-risk population in India | DHR HTAIn | 2023 | 2023 |
| 6. | To determine Cost-effectiveness of Rapid Diagnostic Tests (Hemo Type Sc, Sickle Scan and HPOS) in comparison to solubility test followed by HPLC for Sickle Cell Disease/Trait diagnosis among high risk population in India | DHR HTAIn | 2022 | 2022 |
| 7. | HTA For strengthening prong 2 intervention of PPTCT program at public health facilities through provision of linked HIV and family planning services | DHR HTAIn | 2021 | 2022 |
| 8. | Health Technology Assessment of intravenous Tranexamic acid use in management of Primary Post-Partum Haemorrhage in India | DHR HTAIn | 2020 | 2020 |
| 9. | Health Technology Assessment (HTA) of Uterine Balloon Tamponades to manage Postpartum Hemorrhage in India | DHR HTAIn | 2020 | 2020 |
| 10. | Health Technology Assessment of Long-Acting Reversible Contraceptives in India | DHR HTAIn | 2018 | 2019 |
Publications:
| Sr. No | Citation | Link |
| 1. | Joshi BN, Churasia H, R. R, Shetty s, Kharat N, Begum S, et.al cost effectiveness of lining HIV and family planning services to prevent unintended pregnancies among women living with HIV | PLoS ONE 19 (12) |
| 2. | Padhan A K, Joshi B, Ambadekar N, Rationalizing use of Cardiotocography (CTG) in India for evidence-based decision-making during labour. | J Community Health Manag 2024;11(4):219-221 |
| 3. | Srimathi G, Revathy R, Bagepally B, Joshi B Clinical effectiveness of ferric carboxymaltose (iv) versus iron sucrose (iv) in treatment of iron deficiency anaemia in pregnancy: A systematic review and meta-analysis. | Indian Journal of Medical Research. 2024 Jan 1;159(1):62. DOI: 10.4103/ijmr.ijmr_246_23 (IF 4.2 |
| 4. | Revathy R, Chaurasia H, Shetty S, Joshi B*. Health facility-based interventions and the uptake of contraception among people living with HIV: A systematic review & meta-analysis | Indian Journal of Medical Research. 2023 Nov 1;158(5 & 6):483–93. DOI: 10.4103/ijmr.ijmr_2471_22 (IF 4.2) |
| 5. | Revathy R, Kharat N, Chaurasia H, Shetty S, Begum S, Joshi B, et al. “Health system cost for providing antiretroviral therapy, family planning, and pregnancy‑related services to women living with HIV in public health settings, Mumbai, India”. Indian J Public Health 2023; 67: 428-34. | https://journals.lww.com/ijph/pages/currenttoc.aspx#-2105690237 |
| 6. | Beena Joshi, Akshita Vikani. “Evidence-Based Cost-Effective Interventions for Universal Health Coverage” The Indian Practitioner. 2023 July; 76(7):6-8 | https://theindianpractitioner.com/evidence-based-cost-effective-interventions-for-universal-health- coverage/ |
| 7. | Siddesh Shetty, Kusum Moray, Oshima Sachin, Himanshu Chaurasia, Beena Joshi. “A narrative review comparing clinical effectiveness of commonly used uterine balloon tamponade devices for postpartum haemorrhage management in India”. Int J Reprod Contracept Obstet Gynecol. 2022 Oct;11(10):2924-2942 | https://www.ijrcog.org/index.php/ijrcog/article/view/12089 |
| 8. | Siddesh Shetty, Kusum Moray, Himanshu Chaurasia, Beena Joshi. “Cost of managing atonic postpartum haemorrhage with uterine balloon tamponade devices in public health settings of Maharashtra, India: an economic microcosting study”. BMJ Open 2021;11:e042389. doi:10.1136/ bmjopen-2020-042389 | https://bmjopen.bmj.com/content/11/3/e042389.long |
| 9. | Beena Joshi, Siddesh Shetty, Kusum Moray, Oshima Sachin, Himanshu Chaurasia. “Cost-effectiveness of uterine balloon tamponade devices in managing atonic post-partum hemorrhage at public health facilities in India”. PLoS One. 2021 Aug 18;16(8):e0256271. doi: 10.1371/journal.pone.0256271. | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0256271 |
| 10. | Kusum Moray, Himanshu Chaurasia, Beena Joshi. “Cost-effectiveness of long-acting reversible contraceptive methods: a review”. Int J Reprod Contracept Obstet Gynecol. 2022 Mar;11(3):997-1008 | https://www.ijrcog.org/index.php/ijrcog/article/view/11324 |
| 11. | Kusum Moray, Himanshu Chaurasia, Oshma Sachin, Beena Joshi. “A systematic review on clinical effectiveness, side‑effect profile and meta‑analysis on continuation rate of Etonogestrel contraceptive implant”. Reprod Health. 2021 Jan 6;18(1):4. doi: 10.1186/s12978-020-01054-y. | https://reproductive-health-journal.biomedcentral.com/articles/10.1186/s12978-020-01054-y |
| 12. | Kusum Moray, Beena Joshi, Oshima Sachin, Himanshu Chaurasia, “Cost of providing family planning services & management of pregnancy outcomes at public health facilities in India”. Indian J Med Res. 2022 Jan;155(1):34-42. doi: 10.4103/ijmr.IJMR_146_20. | https://journals.lww.com/ijmr/Fulltext/2022/01000/Cost_of_providing_family_planning_services__.6.aspx |
| 13. | Beena Joshi, Kusum Moray, Oshima Sachin, Himanshu Chaurasia, Shahina Begum. “Cost Effectiveness of Introducing Etonorgestrel Contraceptive Implant into India’s Current Family Welfare Programme. Appl Health Econ Health Policy.” Appl Health Econ Health Policy. 2021 Mar;19(2):267-277. doi: 10.1007/s40258-020-00605-5. | https://link.springer.com/article/10.1007/s40258-020-00605-5 |
| 14. | Beena Joshi, Siddesh Shetty, Kusum Moray, Himanshu Chaurasia, Oshima Sachin. “Cost‑effectiveness and budget impact of adding tranexamic acid for management of post‑partum hemorrhage in the Indian public health system” BMC Pregnancy Childbirth 23, 9 (2023). https://doi.org/10.1186/s12884-022-05308-4 | https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186 /s12884-022-05308-4#:~:text=At%20an%20ICUR%20value%20of,admissions%20per%20100%2C000%20PPH%20cases |
| 15. | Namrata Kharat, Revathy Ramachandra, Himansh Chaurasia, Siddesh Shetty, Shahina Begum, Beena Joshi, Collaborators from study site HIVQOLIn. “Assessment of Health-Related Quality of Life Using EQ-5D-5L Tool with Indian Tariffs Among Reproductive Age Group Women Living with HIV, India “Value in Health regional Issues Sept 2023 | https://www.sciencedirect.com/science/article/abs/pii/S2212109923000468 |
| Policy Briefs | ||
| 1 | Expanding Informed Contraceptive Choice for Indian Women: Will Nexplanon Matter? | https://htain.dhr.gov.in/images/pdf/Policy_Briefs/Policy_Briefs_Vol_1.pdf |
| 2 | Health Technology Assessment of Uterine Balloon Tamponade for Management of Postpartum Haemmorhage in India | https://htain.dhr.gov.in/images/pdf/Policy_Briefs/Policy_Briefs_Vol_1.pdf |
| 3 | To determine Cost effectiveness of Rapid Diagnostic Tests (Hemo Type Sc, Sickle Scan and Sickle Cert) in Comparison to Solubility Test followed by HPLC for Sickle Cell Disease/Trait Diagnosis Among High-Risk Population in India | https://htain.dhr.gov.in/images/pdf/Policy_Briefs/Policy_Brief_Book_vol_2-2023.pdf |
| 4 | Cost-effectiveness of I.V tranexamic acid for treatment of postpartum hemorrhage | https://htain.dhr.gov.in/images/pdf/Policy_Briefs/Policy_Brief_Book_vol_2-2023.pdf |
Contact:
Dr. Beena Joshi
PI HTA Resource Hub
National Institute for Research in Reproductive and Child Health
Jehangir Merwanji Street, Parel, Mumbai, India 400 012
Phone: + (91-22) 2419 2043 / 2132
Email: joshib@nirrch.res.in
Awards:
Awarded “Recognition of Excellence for Best HTAIn Centre” by DHR, held at DHR –ICMR Health Research Excellence Summit, 2024.
